Standard and Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantations (HSCT) From Related and Unrelated Donors for Chronic Lymphocytic Leukemia (CLL). A Long-Term Follow-Up (10 Years) Study From the EBMT Registry

Michallet, Mauricette; Lê, Quoc-Hung; Dreger, Peter; Sobh, Mohamad; Niederwieser, Dietger; Koza, Vladimír; Ruutu, Tapani; Russel, Nigel; Verdonck, Leo F.; Milligan, Donald; Dhédin, Nathalie; Kozák, Tomáš; Boogaerts, Marc; Finke, Juergen; Biezen, Anja van; Brand, Ronald; Witte, Théo de

doi:10.1016/j.bbmt.2008.12.021

Search citation statements

Order By: Relevance

Paper Sections

Select...

Myeloablative or Ric Transplantation?1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2011

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early studies revealed a long-term nonrelapse mortality (NRM) and OS of 46% each [17]. More recent registry data comparing standard with RIC regimens showed a 23% 1-year NRM and 52% 5-year OS for the former, and a 22.5% NRM and 47% OS for the latter, but none of the differences were statistically significant [18].…”

Section: Myeloablative or Ric Transplantation?mentioning

confidence: 99%

Practical Aspects of Allogeneic Hematopoietic Cell Transplantation for Patients with Poor-Risk Chronic Lymphocytic Leukemia

Delgado

Duarte²

2011

The Scientific World JOURNAL

View full text Add to dashboard Cite

Allogeneic hematopoietic cell transplantation has become a viable option for younger patients with poor-risk chronic lymphocytic leukemia. The results obtained with either conventional or reduced-intensity conditioning regimens have been recently evaluated and compared with alternative nontransplant strategies. This manuscript deals with practical aspects of the procedure, including patient and donor selection, conditioning regimen, GVHD prophylaxis, disease monitoring, infectious and noninfectious complications, and timing of the procedure. Finally, we speculate on how we could improve the results obtained with the procedure and new advances currently in clinical trials.

show abstract

Section: Myeloablative or Ric Transplantation?mentioning

confidence: 99%